Epistem is launching Genedrive®, a test that supposedly allows for the early detection of TB and antibiotic resistance without need for central laboratory facilities. However, in a study published earlier this year Epistem's Genedrive demonstrated very poor sensitivity for TB compared to Xpert and smear microscopy.

Epistem has announced that it has reached agreement with Becton Dickinson for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis (excluding India and the Indian Sub Continent) using its Genedrive™ platform. The TB supply and distribution agreement includes an upfront payment of $1m with further milestone payments of up to $3m, alongside escalating supply volumes over the next 5 years.